Clinical Trials Logo

Clinical Trial Summary

This study will link findings from neuroscience with clinical outcomes using contingency management (CM) to identify changes in brain structure and function that emerge during purely behavioral therapy for methamphetamine (MA) use.


Clinical Trial Description

This study will correlate MA-abstinence outcomes from an 8-week program of voucher-based incentives using an escalating schedule for 30 treatment-seeking, MA-dependent individuals with scores on tasks of working memory and assessments of neuropsychological and demographic status. At the beginning and end of the CM program, participants will participate in MRI scans while performing a working memory task and will complete a battery of select neurocognitive and psychological assays to address two specific aims: (1) to determine whether changes in neural function within frontostriatal circuitry from baseline to end of the 8-week CM program are associated with parallel changes in measures of cognitive control and impulsivity and with MA abstinence outcomes and (2) to determine whether structural changes in frontostriatal circuitry over the 8-week CM intervention correspond with neurocognitive, psychological and MA abstinence measures. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02907853
Study type Interventional
Source University of California, Los Angeles
Contact
Status Completed
Phase N/A
Start date September 1, 2015
Completion date February 15, 2018

See also
  Status Clinical Trial Phase
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT03226223 - Pharmacogenetics of Naltrexone for Stimulant Abuse Phase 2
Not yet recruiting NCT05593796 - Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder N/A
Recruiting NCT04616625 - Cardiovascular Effects of Prenatal Methamphetamine Exposure
Completed NCT04061941 - Change in Cognitive Function in Stimulant Users
Completed NCT01967381 - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse Early Phase 1
Terminated NCT01019707 - Safety Assessment of Atomoxetine With MA IV Administration Phase 1
Completed NCT01011829 - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence Phase 2
Active, not recruiting NCT04706624 - Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics N/A
Recruiting NCT05700994 - Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM) N/A
Completed NCT04109014 - FASTLANE II: Reducing Sex, Drug, and Mental Health Risk N/A
Completed NCT03336866 - Study of Antibody for Methamphetamine Outpatient Therapy Phase 1/Phase 2
Completed NCT01822132 - Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade N/A
Completed NCT01062451 - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence Phase 1
Not yet recruiting NCT06233799 - Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder Phase 3
Recruiting NCT05521854 - Contingency Management for Drug Use: Does Age Matter? N/A
Completed NCT01063205 - NAC as a Potential Treatment for Methamphetamine Dependence Phase 1
Not yet recruiting NCT05334914 - ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals N/A
Terminated NCT05034874 - Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 Phase 2